Moreover, entinostat, an oral histone deacetylase (HDAC) inhibitor that inhibits PCa tumor growth in vitro and in vivo in mouse models, has failed to demonstrate efficacy in a small cohort of mCRPC patients [112]. This evidence concerns the gene HDAC9 and posterior cortical atrophy.